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ABSTRACT
Chemoresistance is the major impediment for treating pancreatic cancer. Herb-
derived compound triptolide (TP) can inhibit proliferation of chemo-resistant pancreatic 
cancer (CPC) cell lines through multiple mechanisms, which exhibited superior 
anticancer efficacy compared with gemcitabine. However, toxicity due to non-specific 
exposure to healthy tissues hindered its clinical translation. Herein we successfully 
achieved targeting CPC cells and avoiding exposure to healthy tissues for TP by 
nucleolin-specific aptamer (AS1411) mediated polymeric nanocarrier. We conjugated 
AS1411 aptamer to carboxy terminated poly(ethylene glycol)–block–poly(d, l-lactide) 
(HOOC-PEG-PDLLA), then prepared AS1411-PEG-PDLLA micelle loading TP (AS-PPT) 
through solid dispersion technique. AS-PPT showed more antitumor activity than TP 
and equivalent specific binding ability with gemcitabine-resistant human pancreatic 
cancer cell (MIA PaCa-2) to AS1411 aptamer in vitro. Furthermore, we studied the 
distribution of AS-PPT (Cy3-labed TP) at tissue and cellular levels using biophotonic 
imaging technology. The results showed AS1411 facilitated TP selectively accumulating 
in tumor tissues and targeting CPC cells. The lifetime of the MIA PaCa-2 cell-bearing 
mice administrated with AS-PPT was efficiently prolonged than that of the mice 
subjected to the clinical anticancer drug Gemzar® in vivo. Such work provides a new 
strategy for overcoming the drug resistance of pancreatic cancer.
INTRODUCTION
Pancreatic cancer (PC) is one of the most aggressive 
human malignancies with a historically dismal long-term 
prognosis, which accounts for 2% of all cancers but 6% 
of cancer deaths worldwide [1]. Chemoresistance is the 
major impediment for treating PC, which can arise de 
novo or can be acquired (therapy-induced) refractoriness 
to anticancer chemotherapeutic interventions [2–5]. 
Gemcitabine has been recognized by many oncologists 
as the first-line drug to treat pancreatic cancer, however, 
insensitivity due to singleness of therapeutic target is the 
major concern during its clinical application [6–9]. Hence, 
developing novel chemotherapeutic drug to overcome the 
drug resistance of pancreatic cancer is becoming a real 
challenge.
Chemoresistance in PC is triggered by various 
molecular mechanisms including aberrant gene 
expression, mutations, deregulation of key signaling 
pathways (such as NF-κB, Akt, and apoptosis pathways), 
epithelial-mesenchymal transition (EMT) and the 
presence of stroma cells, highly resistant cells and stem 
cells [2–5]. Each of those mechanisms contributes to drug 
resistance in pancreatic cancer from different aspects, and 
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recommends different therapeutic targets. Triptolide (TP, 
Figure 1 is the structure of Triptolide) is a major active 
compound of Tripterygium wilfordii Hook F, which can 
inhibit proliferation of chemo-resistant pancreatic cancer 
cells (CPC) through multiple pathways, such as inhibition 
of P-glycoprotein, Heat Shock Protein 70 (HSP70), 
NF- κB, Bax gene and angiogenesis, etc, which exhibited 
superior anticancer efficacy compared to gemcitabine and 
taxanes in vitro [6, 10–17]. However, TP-induced toxicity 
due to non-specific exposure to healthy tissues (e.g. liver) 
hindered its clinical translation. In addition, higher 
intratumoral accumulation is difficult for anticancer agents 
with no specific ligands, of note, one major mechanism of 
DR is the efflux of drug from the cell by P-glycoprotein, 
thereby keeping the intracellular levels below the killing 
threshold [18]. Thus, realizing TP selectively targeting 
PC tissues or cells to enhance uptake and simultaneouly 
reduce side effect may be practical to reverse DR with 
longer survival time. 
Nucleolin overexpressed on the plasma membrane 
of PC cells compared with normal cells, which can 
work as a cell surface receptor [19, 20]. Aptamers are 
single-stranded oligonucleotides which can specifically 
recognize and bind to targets by distinct secondary and 
tertiary structures. Aptamer, as target moieties, conjugated 
to nano-vehicles have been studied in many research 
articles [21–24]. Nucleolin-specific aptamer (AS1411, 
5′GGTGGTGGTGGTTGTGGTGGTGGTG G-3) is a 
G-rich phosphodiester oligonucleotide with high affinity 
and specificity to nucleolin, which has been proved to 
be safe in clinical research [25]. Then, this provide us an 
inspiration of developing AS1411-mediated nanoparticle 
to achieve CPC-specific delivery of TP.
In pilot study, we have developed triptolide-polymeric 
micelle (TP-PM) by polymer-based delivery system, which 
not only overcame the pitfall of hydrophobicity, but also 
facilitated TP passively accumulating in cancerous tissues 
based on the Enhanced Permeability and Retention (EPR) 
effect [26]. Nevertheless, as passive targeting nanoscale 
preparations, TP-PM suffers from some limitations including 
the degree of tumor vascularization and angiogenesis, high 
interstitial fluid pressure of solid tumors leading to drug 
expulsion and opsonins interaction, etc [27, 28], which 
limited its therapeutic effect. Herein, we conjugated AS1411 
to TP micelle composed with poly(ethylene glycol)–block–
poly (D, L-lactide) (PEG- PDLLA) diblock copolymers, 
which was termed AS- PPT (Figure 2). PEG-PDLLA was 
chosen as a drug carrier for TP due to its biodegradability 
and biocompatibility properties, which has been applied in 
the formulation of Genexol-PM® for treatment of metastatic 
carcinoma of ovary and breast after failure of first-line 
or subsequent chemotherapy [29, 30]. In this study, we 
investigated the tissue and cellular levels distribution of AS-
PPT (Cy3-labed TP) using biophotonic imaging. The results 
showed AS1411 could facilitate TP selectively targeting 
CPC cells and accumulating in tumor tissues. In addition, 
AS- PPT possess more antitumor efficacy than nontargeted 
TP-PM in a xenograft mouse model of gemcitabin-
resistant human pancreatic cancer (MIA PaCa-2), 
and the lifetime of the MIA PaCa-2 cell-bearing mice 
administrated with AS-PPT was efficiently prolonged 
than that of the mice subjected to the clinical anticancer 
drug Gemzar® in vivo. These indicated AS1411 aptamer 
can facilitate TP selectively targeting CPC cells and 
accumulating in tumor tissues, AS-PPT may be a potential 
active targeting drug for CPC.
Figure 1: Chemical Structures of triptolide.
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Figure 2: Schematic representation of synthesizing AS1411-PEG-PDLLA and preparing smart triptolide nanomedicine, 
which selectively targeting CPC cells.
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RESULTS AND DISCUSSION
Characterization of AS1411-PEG-PDLLA 
polymer and AS-PPT
AS1411 aptamer, HOOC-PEG-PDLLA and AS- PP 
polymer were characterized by mass spectrometry 
(MS), 1H-NMR and polyacrylamide gel electroporesis 
(PAGE) respectively. The results were shown in Figure 3. 
Figure 3A (a) showed the molecular weight of NH2-
AS1411 aptamer was 8486.0. Figure 3A (b) was the 
1H-NMR spectrum of HOOC-PEG-PDLLA polymer 
material. PAGE was utilized to examine the conjugation 
of AS1411 to HOOC-PEG-PDLLA, and to demonstrate 
successful removal of unconjugated aptamers after 
the reaction. The mixing of aptamer and NPs without 
the addition of the coupling agent (AS+PP, Figure 3B 
(e)) did not show any band of conjugated aptamer after 
repetitive washing by ultracentrifugation (10000 × g, 
15°C, 15 minutes) in centrifugal filter tubes (MWCO 10k), 
indicating a lack of non-specific interaction between the 
aptamer and HOOC-PEG-PDLLA. However, conjugation 
with the addition of EDC (AS-PP, Figure 3B (d)) leads 
to RNA bands consistent with RNA covalently bound to 
the HOOC-PEG-PDLLA even after the same repetitive 
washing by ultracentrifugation, which indicated AS1411-
PEG-PDLLA polymer was obtained.
AS-PPT was prepared by solid dispersion technique 
using MPEG-PDLLA and AS-PP polymer (10:1). The 
appearance of AS-PPT was shown in Figure 4A, and 
the clear solution could be observed. DL and EE can be 
changed through varying the mass ratio of TP / carrier, 
and the highest DL and EE can reach to 6.1 ± 0.10% and 
97.1 ± 1.01%, respectively. The AS-PPT (DL = 4%) was 
chosen to characterize in detail. The average size of AS-
PPT was about 41.7 ± 1.5 nm (Figure 4B.) and PDI was 
0.100 ± 0.023. Li Tang and his coworkers have proved that 
the 50 nm nanomedicine have highest anticancer effect for 
its highest tumor tissue retention, penetration and efficient 
cancer cell internalization [31]. This maybe one reason 
for its higher anticancer effect in the following studies. 
Figure 4C was the TEM image of AS-PPT in water, which 
showed AS-PPT were uniform and spherical shapes in 
solution, and such Figure was consisted with the result 
tested by Malvern Nano-ZS 90 laser particle size analyzer.
The selectivity and antitumor activity of 
AS-PPT in vitro
To confirm the specific binding ability of AS-PPT to 
cancerous cells, either the Cy3-labeled TP loaded in AS-
PPT or Cy3-labeled TP loaded in TP-PM were incubated 
with human pancreatic carcinoma cell line MIA PaCa-2 and 
human liver cell line L-02 respectively. Figure 5 (A1–D1) 
and Figure 5 (A2–D2) were the cell images observed with 
interference-phase contrast microscope and fluorescence 
microscope, respectively, and Figure 5 (A3–D3) were their 
overlay images. Figure 5A2 showed the close fluorescence 
intensity with Figure 5B2, which illustrated AS-PPT had 
no specific-targeting L-02 cells compared with TP-PM, in 
addition, the Figure 5A3 and Figure 4B3 further confirmed 
such results. In contrast, MIA PaCa-2 cells in AS-PPT 
group (Figure 5D2) showed stronger fluorescence intensity 
than that of TP-PM group (Figure 5C2). Especially, 
Figure 3: Characterization of A (a). The MS spectrum of Nucleolin Aptamer (AS1411-NH2). A(b).The 1H NMR spectrum of 
HOOC-PEG-PDLLA polymeric material. Characterization of B (a). Marker1 50 bp, B (b). Marker2 25 bp, B (c).AS1411 aptamer 
(MW = 8486), B (d). AS1411-PEG-PDLLA (AS-PP), B (e).The physical mixture of AS1411 and HOOC-PEG-PDLLA without the addition 
of the coupling agent.
Oncotarget8364www.impactjournals.com/oncotarget
Figure 5D3 showed stronger red fluorescence signal in MIA 
PaCa-2 cells than that of Figure 5C3, which implied AS-
PPT group had higher internalizing ability with MIA PaCa-
2 cell than that of TP-PM group. This should be attributed 
to the specific binding ability of AS1411 aptamer with 
nucleolin overexpressed on the surface of cancerous cells.
Considering the controlled-release behavior of 
TP-PM and AS-PPT [26], we compared the cytotoxicity 
of them with free TP and Gemcitabine on MIA PaPa-
2 cells for 48 h. The viability of cells was measured 
consecutively at arranged time points using MTT assays. 
The results showed that the presence of TP, TP-PM and 
AS-PPT significantly reduced MIA PaPa-2 cell viability 
in a dose-dependent manner (Figure 6). It seemed that 
AS-PPT and free TP have the same antitumor activities, 
but more activities than TP-PM in vitro, which might be 
ascribed to the mediation of AS1411 strengthening the 
cell endocytosis of AS-PPT. Compared with Gemcitabine, 
lower nanomolar concentrations of each TP formulation 
induced pancreatic cancer cell death, indicating TP 
exhibited more antitumor activities than Gemcitabine 
in vitro.
In vivo distribution studies
To evaluate whether the AS1411 aptamer-mediated 
nanocarrier loading TP can indeed specifically targeting 
tumors, we used biophotonic imaging technology to 
examine the tissue distribution of Cy3-labeled TP 
delivered by TP-PM and AS-PPT. Figure 7 showed that 
both formulations were prone to accumulate in liver and 
kidney for the initial 6 h, which should be attributed to 
the rapid uptake by mononuclear phagocyte system (MPS) 
and glomerular filtration [32, 33]. The tumor of two 
groups showed the same fluorescence signals intensity at 
6h, which should be ascribed to their nanostructure, this is 
also in line with the findings of Li Tang [31]. In contrast, 
the fluorescence signal intensity of AS-PPT in tumor were 
significantly higher than that of TP-PM at 12 h (Figure 7), 
which may be attribute to that AS1411 aptamer-mediated 
nanoparticle interacted highly with the cancerous cells 
and inhibited the efflux of AS-PPT from the cell by 
P-glycoprotein. In addition, other tissues such as spleen 
and lung of TP-PM group showed negligible fluorescence 
signal at 6 h post-injection. And the fluorescence signals 
in heart, spleen and lung were hardly detected in AS-PPT 
administration group at either 6 h or 12 h.
In vivo pharmacodynamics of AS-PPT
To evaluate the pharmacodynamics of AS-PPT, 
we compared the in vivo antitumor efficiency of TP-PM, 
AS-PPT and Gemzar® in xenograft mouse model of MIA 
PaCa-2. When the treatment began, the body weight and 
tumor volume were monitored and calculated every two 
days. The results were shown in Figure 8. We found that 
TP-PM and AS-PPT can significantly inhibited tumor 
growth compared with negative control (NS) and positive 
control (Gemzar®), and the therapeutic group (AS-PPT) 
showed the slowest growth rate of tumor volume among 
the four groups. From the Figure 8A, we can see that 
TP- PM, AS-PPT and Gemzar ® group showed similar 
growth rate of tumors during the early stage, furthermore, 
both the TP-PM and AS-PPT group showed slower 
tumor growth rate during the late stage of treatment, 
especially, that of AS-PPT group was the slowest among 
four groups, the reason might be the sustained release of 
TP from AS-PPT and higher AS-PPT accumulation in 
Figure 4: Preparation of AS-PPT (A) Morphology of AS-PPT. (B) Particle size. (d = 42 nm, PDI = 0.109. (C) TEM image of AS-PPT. 
Scale bars were 100 nm.
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cancerous cells mediated by AS1411 aptamer. There were 
significant differences between positive group (Gemzar ®) 
and therapeutic groups , respectively (*P < 0.05). Weight 
profiles showed a largish loss within the first week in 
negative control group (NS), TP-PM and AS-PPT groups 
than that of positive control group (Gemzar®), whereas 
the body weight of the mice in three therapeutic groups 
(TP-PM, AS-PPT, Gemzar®) all exhibited steady increase 
than that of negative control group after the 10th day 
(Figure 8B). Contrary to our expectation, the body weight 
of positive control group (Gemzar®) exhibited higher 
increase than that of TP-PM and AS-PPT group, the reason 
should be the toxicity of TP released from delivery system, 
which bring the discomfort to mice.
Evaluation of the effect of AS-PPT on mice survival 
was accomplished and displayed in Figure 8C. It can 
Figure 5: Cellular selectivity: The fluorescence intensity of cy3-labeled TP encapsulated by TP-PM and AS-PPT after 
incubation with human liver cell line L-02 and human pancreatic carcinoma cell line MIA PaCa-2 for 2 h, respectively. 
(A1, B1, C1, D1) were the cell images observed with interference-phase contrast microscope. (A2, B2, C2, D2) were the cell images 
observed with fluorescence microscope. (A3, B3, C3, D3) were the aforementioned overlay images. (×200).
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Figure 6: Cytotoxicity of different concentration of TP formulation and Gemzar® on MIA PaCa-2 cell line after 
incubated for 48 h. Error bars represent the standard deviation (n = 6).
Figure 7: Tissue distribution: Localization of Cy3-labeled TP by biophotonic imaging-based analysis after 
administration of rats with TP-PM and AS-PPT at 6 h and 12 h time point. The intensity of fluorescence signal in the isolated 
hearts, livers, spleens, lungs, kidneys and tumor were presented.
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be seen that more than half of mice in negative control 
group and positive control group died within 10, 20 days, 
respectively. Half of mice in TP-PM group died within 
18 days, however, the mice with 40% survived for 24 days. 
In contrast, the therapeutic group administrated AS-PPT 
still remained half mice after 24 days. Significance were 
assessed compared with the control group of Gemzar ® 
(*p < 0.05). 
Figure 9 (A, B, C, D). represents an optical 
micrograph of tumor tissue of mice treated with NS, 
Gemzar®, TP-PM and AS-PPT, respectivley. Many 
scattered focal cancer cell nests are in gland tube-like 
arrangement with red blood cell aggregation within the 
lumen, in addition, the tissue necrosis and inflammatory 
cell infiltration can be observed in Figure 9A. All these 
indicated the NS has no inhibition of cancer cells. Figure 9B 
shows a wide range of cancer cell necrosis and 
inflammatory cell infiltration, indicating Gemazar with 
good effect for inhibiting cancer cells. Figure 9C is the 
group with administration of TP-PM, from the figure, 
we can find a lot of necrotic tissue and inflammatory 
cell infiltration, indicating that TP-PM has good 
anti-gemcitabin-resistant pancreatic cancer efficacy, 
these should be ascribed to nanocarrier facilitating TP 
with multiple therapeutic target accumulating in tumor 
tissue. From the Figure 9D, a lot of cancer cells undergo 
apoptosis, scattered focal cancer cell nests arranged in 
gland tube-like. AS-PPT exhibited superior anticancer 
efficacy compared to Gemazar® group and TP-PM group, 
which should be attributed to AS1411 aptamer provide 
AS-PPT an approach to achieve nucleolin-specific 
delivery and promoting endocytosis of cancerous cells for 
AS-PPT, which is also consistent with the survival results.
CONCLUSION
Effective treatment of pancreatic cancer is a long 
cherished object for medical workers. A viable strategy 
have been developed, such as surgery, radiotherapy 
and chemotherapy, etc. However; each suffers its own 
specific limitations mainly arising from local recurrence 
and metastatic spread of such disease. Pathological site-
specific delivery of active agents was considered to be 
Figure 8: (A) Tumor volume changes of MIA PaCa-2 cell–xenografted BALB/c nude mice after treatment, significance were assessed 
compared with Gemzaer, *p < 0.05 (B) Body weight changes of BALB/c nude mice after treatment. (C) Survival rate of mice. (10 mice 
each group), significance were assessed compared with TP-PM, Gemzaer, *p < 0.05.
Oncotarget8368www.impactjournals.com/oncotarget
a perfect strategy. Nanoscience generated nano-sized 
carriers provides potential to realize such purpose based on 
EPR effect, however, the sole nanocarrier with no specific 
ligands are not sufficient to deliver drugs to target sites. 
Nowadays, ligand-modified nanoscale preparations have 
been considered to effectively improve the anti-tumor 
efficacy based on EPR effect and subsequent endocytosis 
of cancerous cells via ligand–receptor interaction. As 
one of the most excellent targeting ligands, aptamers can 
selectively bind to a variety of targets ranging from small 
molecules to whole cells due to their three-dimensional 
structures even without knowledge of characteristic 
protein profiles on cell surface. Triptolide posses multiple 
therapeutic targets for cancer, however, hydrophobicity 
and toxicity due to non-specific exposure to healthy tissues 
hindered its clinical translation. Currently, we constructed 
AS1411 aptamer modified PEG-PDLLA micelle loading 
TP with an average diameter of 41.7 ± 1.5 nm. The in vitro 
results showed that AS-PPT had specific binding ability 
with human pancreatic carcinoma cell (MIA PaCa-2) but 
no specific-targeting L-02 cells compared with TP-PM. 
This should be attributed to the specific binding ability 
of AS1411 aptamer with nucleolin overexpressed on the 
surface of cancerous cells.
In vivo tumor inhibition study revealed that the 
AS-PPT has superior anti-tumour efficacy on PC cells 
when compared with TP-PM and Gemzar® . Furthermore, 
in vivo distribution studies showed AS-PPT kept more TP 
accumulation in tumor and extend tumor residence than 
TP-PM, this should be attribute to the specific interaction 
between AS1411 aptamer and nucleolin significantly 
enhanced cellular uptake of AS-PPT and inhibited the 
efflux of AS-PPT from the cell by P-glycoprotein. Based 
on the foregoing experimental data, we concluded that 
AS1411 aptamer-medicated nanocarrier can facilitate 
TP accumulating in tumor tissues via EPR effect, when 
they entered the tumor interstitial space, AS1411 aptamer 
presented on the AS-PPT surface quickly recognized 
cancerous cell followed by AS1411-nucleolin interaction, 
and consequently enhanced the inhibition of tumor growth. 
In conclude, AS-PPT have great potential for reversing the 
drug resistance of pancreatic cancer.
Figure 9: Light micrographs of tumor in mice treated with (A) NS, (B) Gemzar, (C) TP-PM, and (D) AS-PPT (×400): which were 
collected from mice after the last treatment and were stained haematoxylin and eosin.
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MATERIALS AND METHODS
Materials
Materials used included D,L-lactide (Aldrich, USA), 
monomethoxy poly(ethylene glycol) (MPEG2000, Aldrich, 
USA), stannous octoate (Sn(Oct)2). The carboxy terminated 
poly(ethylene glycol)–block–poly(d,l-lactide) (HOOC-
PEG2000-PDLLA6000) was purchased from Xi’an ruixi 
Biological Technology Co.,Ltd (China). Aptamer NH2-
AS1411 (5′GGTGGTGGTGGTTGT GGTGGTGGTGG-
3′-NH2) and Sulfo-Cyanine3-Triptolide (Cy3-TP) 
were purchased from Guangzhou RiboBio Co., Ltd 
(Guangzhou, China). Dulbecco’s modified Eagle’s medium 
(DMEM), 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl 
tetrazolium bromide (MTT, Sigma, St. Louis, MO). 
Dehydrated alcohol, dimethylformamide (DMF), 
acetonitrile, dichloromethane (DCM) and petroleum ether 
were purchased from Huasheng Chemicals (Qingdao, 
China), dimethyl sulfoxide (DMSO, Huasheng Chemicals, 
Qingdao, China), Gemcitabine hydrochloride for injection 
(Gemzar®) was purchased from Eli Lilly Co, Ltd and 
triptolide (TP, Purity > 99%) was bought from Chengdu 
Biopurify Phytochemicals Co, Ltd (Chengdu, China). 
Gemcitabin-resistant human pancreatic cancer cell 
line (MIA PaCa-2) and human liver cell line L-02 were 
purchased from Shanghai Bioleaf Biotech Co.,Ltd. BALB/c 
nude mice (8–10 weeks, 20 ± 2 g) were obtained from the 
Institute of Experimental Animals in Chinese Academy of 
Medical Science. 
The animals were housed at temperature of 
20–22°C, relative humidity of 50–60% and 12 h light-
dark cycles. Free access to food and water was allowed. 
All animals would be in quarantine for a week before 
treatment. All animals care and experimental procedures 
were conducted according to Institutional Animal Care 
and Use guidelines.
Synthesis and characterization of AS1411-PEG-
PDLLA polymer
AS1411-PEG2000-PDLLA6000 polymer was 
synthesized by EDC/NHS technique [34, 35] Briefly, some 
HOOC- PEG2000-PDLLA6000 polymer suspended in 5ml 
DNase/RNase-free water (10 μg/μL) were incubated with 
200 μL EDC (400 mM) and 200 μL NHS (200 mM) for 
30 min at room temperature with gentle shaking. The NHS-
activated nanomicelle were reacted with 3′-amino-RNA 
aptamer (5′GGTGGTGGTGGTTGTGGTGGTGGTGG-
3′-NH2, 1 μg/μL). The reaction was lasted for 2 h with 
constant mixing at room temperature. Then the resulted 
AS1411- PEG2000-PDLLA6000 polymer (AS-PP) were 
purified with DNase/RNase-free water (15 mL) by 
ultrafiltration (10000 × g, 15°C, 15 minutes) in centrifugal 
filter tubes (MWCO 10 k). The AS-PP polymer were 
resuspended in DNase/RNase-free water and then 
lyophilized to be dried powder for further use. The 
preparative process was shown in the Figure 2.
The AS-PP polymer was confirmed on 10% TBE-
Urea PAGE. HOOC-PEG-PDLLA Nano-micelle were 
incubated as above without the crosslinker (−EDC) to 
confirm covalent conjugation. AS-PP (+EDC), AS+PP 
(−EDC) were separated by PAGE. The molecular weight 
(MW) DNA marker and free aptamer served as standards 
for 50 and 25 base pair band on the gel.
Preparation and characterization of TP-PM and 
AS-PPT
Preparation of TP-PM
The synthesis, preparation and characteristics of 
MPEG2000–PDLLA6000 diblock copolymers and TP-PM 
have been described in our previous publications [26, 35]. 
To prepare TP-PM, some MPEG-PDLLA copolymer and 
TP were dissolved in 3 mL of dehydrated acetonitrile 
under vigorous stirring. After all contents were dissolved, 
the solution was evaporated on a rotary evaporator under 
reduced pressure at 60°C. Upon acetonitrile evaporation, 
a homogenous coevaporation was obtained. TP was 
distributed into polymeric carriers in an amorphous form. 
Then, the coevaporation was dissolved in 5 ml of water at 
65°C to create the TP polymeric micelle solution, and the 
solution was filtered with a 0.22 μm filter to obtain a clear 
solution. Then, the solution was lyophilized in a freeze dry 
system to obtain a dried powder. 
Preparation of AS-PPT
PEG2000-PDLLA6000 copolymer and AS-PP freeze-
dried powder (at a ratio of 10:1), TP were dissolved in 
500 μL of dehydrated acetonitrile under vigorous shaking. 
After all contents were dissolved, the solution was 
evaporated under reduced pressure at 60°C. Then, the 
coevaporation were dissolved in 1 ml of water at 60°C to 
create the AS-PPT solution, and the solution was filtered 
with a 0.22 μm filter to obtain a clear solution. Then, the 
solution was lyophilized in a freeze dry system to obtain 
a dried powder. 
The drug loading (DL) and encapsulation efficiency 
(EE) of AS-PPT were determined as follows: First, a 
standard absorbance curve was established with a series 
of standard TP solution to facilitate the determination 
of the exact amount of drug within the TP-PM and AS-
PPT (data not shown). Determination of the TP quantity 
within the AS-PPT was done by high-performance liquid 
chromatography (HPLC. The column temperature was 
30 °C. The mobile phase was composed of methanol/
acetonitrile/water (15/20/65, v/v/v %). The flow rate was 
1.0 mL/min and the detection wavelength is 218 nm. 
Based on this data, the DL and EE of TP-PM and AS-PPT 
were calculated according to eqn. (1) and (2):
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DL TP=
Amount of the Powder
× %100  (1)
EE = ×DL
Amount of TP in feed
100%  (2)
The particle size of prepared AS-PPT nano-micelle 
was determined using a Malvern Nano-ZS 90 laser 
particle size analyzer after equilibration for 10 min. 
The morphological characteristics of the AS-PPT were 
examined by transmission electron microscope (TEM, 
H-6009IV, Hitachi, Japan).
The Selectivity and antitumor activity of AS-PPT 
in vitro
To confirm the specific binding ability of AS-PPT 
to cancer cells, the AS-PPT (Cy3-labeled TP) and the TP-
PM (Cy3-labeled TP) were respectively incubated with 
human pancreatic carcinoma cell line MIA PaCa-2 and 
human liver cell line L-02. Briefly, cells were plated at 
a density of 1 × 104 cells per well in 100 μL of DMEM 
medium in 96-well plates and grown for 24 h. The cells 
were then exposed to TP-PM and AS-PPT at the same 
concentrations of cy3-labeled TP for 2 h. After incubation, 
the cells were washed using PBS buffer solution for three 
times to remove the free TP, TP-PM and AS-PPT. Then the 
cells were observed with fluorescence microscope. 
To confirm whether AS-PPT have more antitumor 
activity than free TP, TP-PM and Gemzar®, the MIA 
PaCa-2 cells were incubated with the different TP 
concentrations of free TP solution , TP-PM, AS-PPT and 
Gemzar® for 48 h at 37 oC. After that, the viability of cells 
was measured consecutively at arranged time points using 
3-(4,5-dimethylthiazole-2-yl)-2,5-di-phenyl tetrazolium 
bromide (MTT, Sigma-Aldrich) assays. 
All the results obtained from MTT assays were 
confirmed by repeating at six individual experiments, and 
all data were expressed as the mean ± S.D.
The tissue distribution and pharmacodynamics 
of AS-PPT in a xenograft mouse model of CPC
Tissue distribution
For visually showing the tissue distribution of 
AS-PPT in animal model of CPC, fluorescence imaging 
will be performed using an IVIS® 200 imaging system. 
Eight eight-week-old healthy female BALB/c nude mice 
(18–20 g body weight) will be inoculated with 100 μl 
of MIA PaCa-2 cell (1 × 107/ml) suspended in normal 
saline on the right flank. Tumor size will be measured 
every other day using vernier calipers in two dimensions. 
Individual tumor volumes (V) were calculated using the 
formula V = [length × (width)2 ] M/2, where length is 
the longest diameter and width is the shortest diameter 
perpendicular to length. Once the tumors reached 
200 mm3, the mice will be randomly divided into 2 groups 
(n = 4 for each group), and respectively subjected to 
TP-PM and AS-PPT at the same dose of 0.2 mg/ kg 
of cy3-labeled TP via tail vein injection. Two mice 
of each group will be sacrificed at 6 h and 12 h after 
the administration and the major organs (heart, liver, 
spleen, lung, kidney and tumor) will be collected. The 
fluorescence signal of those organs in each group will be 
detected using Xenogen IVIS imaging system (Xenogen 
Imaging Technologies, Alameda, CA). Excitation (λex = 
445–490 nm) and Emission (λem = 515–575 nm) filters 
were used. Identical illumination settings including 
exposure time (5 s), binning factor (4), f-stop (2) and 
fields of view (15 cm for width and length, respectively), 
will be used for all image acquisition. Fluorescent and 
photographic images will be acquired and overlaid. The 
in vivo experiments were performed in accordance with 
institutional guidelines and in compliance with national 
and international law and policies. All efforts were made to 
minimize the number of animals used and their suffering.
 Pharmacodynamics
Briefly, fifty two eight-week-old healthy female 
BALB/c nude mice (18–20 g body weight) were injected 
subcutaneously on the right back with 0.1 mL of cell 
suspension containing MIA PaCa-2 cell (1 × 107/ml). 
Treatment was initiated when the tumor reached a size of 
approximately 200 mm3, the mice were randomly divided 
into four groups containing thirteen animals and samples 
were administered via vein once a week for three weeks. 
Group 1 kept as the negative control group and receive 
0.1 mL dose of normal saline (NS), group 2 received 
0.1 mL of Gemzar® with 20 mg/kg (as the positive control 
group), group 3 received 0.1 mL of TP-PM with dosage 
of 0.32 mg/kg TP and group 4 received 0.1 mL of AS-
PPT with dosage of 0.32 mg/kg TP. During this period, 
the mice were observed continuously for relevant indexes, 
such as body weight, tumor volume and survival rate. 
Three mice of each group were sacrificed on the 3th 
week post-treatment and the tumor were harvested and 
fixed in 10% buffered formaldehyde solution and then 
embedded in paraffin. Sections of 3–5 mm were stained 
with hematoxylin and eosin (H & E) and observed on light 
microscope and electron microscopic measurements.
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